US 12,403,138 B2
Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
John M. Sedivy, Barrington, RI (US); Gerwald Jogl, Pawtucket, RI (US); and Alexandra D'Ordine, Lakeville, MA (US)
Assigned to Brown University, Providence, RI (US)
Appl. No. 17/778,369
Filed by Brown University, Providence, RI (US)
PCT Filed Nov. 23, 2020, PCT No. PCT/US2020/061842
§ 371(c)(1), (2) Date May 19, 2022,
PCT Pub. No. WO2021/102423, PCT Pub. Date May 27, 2021.
Claims priority of provisional application 63/077,888, filed on Sep. 14, 2020.
Claims priority of provisional application 62/939,564, filed on Nov. 22, 2019.
Prior Publication US 2023/0139684 A1, May 4, 2023
Int. Cl. A61K 31/167 (2006.01); A61K 31/145 (2006.01); A61K 31/166 (2006.01); A61K 31/17 (2006.01); A61K 31/198 (2006.01); A61K 31/366 (2006.01); A61K 31/381 (2006.01); A61K 31/4035 (2006.01); A61K 31/4192 (2006.01); A61K 31/423 (2006.01); A61K 31/445 (2006.01); A61K 31/4741 (2006.01); A61K 31/505 (2006.01); A61K 31/53 (2006.01); A61K 31/635 (2006.01); A61K 31/64 (2006.01)
CPC A61K 31/4741 (2013.01) [A61K 31/145 (2013.01); A61K 31/166 (2013.01); A61K 31/167 (2013.01); A61K 31/17 (2013.01); A61K 31/198 (2013.01); A61K 31/366 (2013.01); A61K 31/381 (2013.01); A61K 31/4035 (2013.01); A61K 31/4192 (2013.01); A61K 31/423 (2013.01); A61K 31/445 (2013.01); A61K 31/505 (2013.01); A61K 31/53 (2013.01); A61K 31/635 (2013.01); A61K 31/64 (2013.01)] 7 Claims
 
1. A method for treating an age-associated inflammation in a patient in need thereof, the method comprising administering a therapeutically effective amount of a long interspersed nuclear element-1 (L1) endonuclease (EN) inhibitor to the patient, wherein the L1 EN inhibitor is AD11 of the chemical structure shown below:

OG Complex Work Unit Chemistry
(AD11); and
wherein the age-associated inflammation is in a patient having Alzheimer's disease.